GZGan Zhang

Gan Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gan Zhang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Bingjie Wang

    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China

    1 shared publication
  • Dan Zhou

    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China

    1 shared publication
  • Feiyang Yu

    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China

    1 shared publication
  • Ge Gao

    Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China

    1 shared publication
  • Haiyan Zhao

    State Key Laboratory of Virology and Biosafety, College of Life Sciences, Wuhan University, Wuhan, China

    1 shared publication
  • Hang Liu

    Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China

    1 shared publication

Latest Publications

  • Open Access

    An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection

    by Dan Zhou, Rao Cheng, Yanfeng Yao, Gan Zhang, Xin Li, Bingjie Wang, Yong Wang, Feiyang Yu, Shangyu Yang, Hang Liu, et al.

    Nipah virus (NiV) is a zoonotic emergent paramyxovirus that can cause severe encephalitis and respiratory infections in humans, with a high fatality rate ranging from 40% to 75%. Currently, there are no approved human vaccines or antiviral drugs against NiV. Here, we designed a ferritin-based self-assembling nanoparticle displaying the NiV G head domain on the surface (NiV G-ferritin) and assessed immune responses elicited by the soluble NiV G head domain (NiV sG) or NiV G-ferritin. Immunization with NiV G-ferritin or NiV sG conferred complete protection against lethal NiV challenge without detection of viral RNA in Syrian golden hamsters. Compared to NiV sG, NiV G-ferritin induced significantly faster, broader, and higher serum neutralizing responses against three pathogenic henipaviruses (NiV-Malaysia, NiV-Bangladesh, and Hendra virus). Moreover, NiV G-ferritin induced a durable neutralizing immunity in mice as antisera potently inhibited NiV infection even after six months of the third immunization. Additionally, we isolated a panel of 27 NiV G-binding monoclonal antibodies (mAbs) from NiV G-ferritin immunized mice and found that these mAbs targeted four distinct antigenic sites on NiV G head domain with two sites that have not been defined previously. Notably, 25 isolated mAbs have potent neutralizing activity with 50% inhibitory concentrations less than 10 ng/mL against NiV pseudovirus. Collectively, these findings provide new insights into the immunogenicity of NiV G protein and reveal that NiV G-ferritin is a safe and highly effective vaccine candidate against Nipah virus infection.